Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048266 · ClinicalTrials.gov registry record
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
A clinical trial of Multiple Endocrine Neoplasia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 629
- Enrollment target
- 1
- Study location
NCT03048266: Recruiting study of Multiple Endocrine Neoplasia, sponsored by M.D. Anderson Cancer Center.
NCT03048266 is a study of Multiple Endocrine Neoplasia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 629 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03048266, a study of Multiple Endocrine Neoplasia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 629 participants
- Enrollment target
- 1
- Study location
Study Summary
Objectives: The aim of the present study is to assess the significance of metabolomics and genetics in diagnosing and survival evaluation for pNET in the periodic follow-up of MEN1 patients. Aim 1: To evaluate the relationship of serum global metabolic profiles with subsequent development of aggressive PNET and evaluate patients survival in a nested case-control study of MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have developed non-aggressive PNETs (controls). Aim 2: Validate the top serum metabolites identified from Aim 1 in MEN1 patients who have developed aggressive PNETs and MEN1 patients who have developed non-aggressive PNETs, using a targeted metabolomics approach. Aim 3: Prospectively identify the potential miRNA biomarkers of serum with miRNA sequencing in MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have developed non-aggressive PNETs (controls). Aim 4: Validate the potential miRNA biomarkers identified from Aim 1 in MEN1 patients who have developed aggressive PNETs and in MEN1 patients who have developed non-aggressive PNETs, using a targeted qRT-PCR approach (in serums), as well as to see the relationship of potential miRNA biomarkers with patients survival.
Primary Outcome
Review of samples from 50 cases (aggressive PNET) and 50 controls (non-aggressive PNET).
Conditions Studied
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 629 participants |
| Start Date | 2015-11-05 |
| Est. Completion | 2026-11-01 |
What NCT03048266 shows while recruiting
NCT03048266 is an observational study that tracks outcomes without assigning an intervention. The registered 629 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Multiple Endocrine Neoplasia appearing as the primary indexed condition, and to 0 interventions.
NCT03048266 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03048266 about?
NCT03048266 is a clinical study titled "Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients". Objectives: The aim of the present study is to assess the significance of metabolomics and genetics in diagnosing and survival evaluation for pNET in the periodic follow-up of MEN1 patients. Aim 1: To evaluate the relationship of serum global metabolic profiles with subsequent development of aggre...
What is the current status of trial NCT03048266?
This trial is currently recruiting. The enrollment target is 629 participants. The study started on 2015-11-05. Estimated completion is 2026-11-01.
What conditions does trial NCT03048266 study?
This clinical trial studies the following conditions: Multiple Endocrine Neoplasia.
Who is sponsoring clinical trial NCT03048266?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03048266 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Endocrine Neoplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI